MARKET

PFE

PFE

Pfizer
NYSE

Real-time Quotes | Nasdaq Last Sale

36.52
-0.18
-0.49%
After Hours: 36.62 +0.1 +0.27% 19:59 11/23 EST
OPEN
37.03
PREV CLOSE
36.70
HIGH
37.09
LOW
36.21
VOLUME
43.67M
TURNOVER
--
52 WEEK HIGH
41.99
52 WEEK LOW
26.43
MARKET CAP
203.05B
P/E (TTM)
24.55
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Japan stocks set to trade higher amid Covid vaccine hopes; Biden picks Yellen as Treasury secretary
Investor focus on Tuesday will likely be on the continued positive momentum surrounding the race for a coronavirus vaccine.
CNBC.com · 3h ago
Too Early to Call BioNTech the Winner in the COVID-19 Vaccine Race, Says Analyst
Unfortunately, Covid-19 is still on the rampage across the globe. However, the good news is that the newest data coming from late stage studies indicates a vaccine may soon become widely available.  Amongst the candidates entering the final stretch is BNT162b2, the result of a collaboration between BioNTech (BNTX) and Pfizer (PFE). The final efficacy analysis from the Phase 3 trial showed the vaccine had a 95% success rate in preventing the coronavirus, far above the 50% required by the FDA in order to gain regulatory approval. The partnership has filed for Emergency Use Authorization (EUA), and an FDA advisory committee is set to meet on December 10 to discuss the way forward.H.C. Wainwright analyst Robert Burns believes there is a “high likelihood that the FDA advisory committee shall recommend approval of BNT162b2.”This is obviously good news, but what does it mean specifically for BioNTech investors? Here Burns doesn’t exude as much confidence.The Covid-19 vaccine space is crowded, with other programs nearing the finish line, too. Different candidates have differentiating features setting them apart from one another. A drawback for BioNTech/Pfizer’s offering is its need to be stored at ultra-low temperatures; at -94°F for up to six months or up to five days at 36-46°F.The 5-star analyst highlights how this potential limitation can impact its success when compared to other candidates.“For instance,” Burns noted, “Moderna recently announced that its mRNA-1273 can be stored at 36-46°F for up to 30 days and maintains stability at room temperature for 12 hours. Furthermore, CureVac has stated that CVnCoV is stable for at least three months at refrigerated temperatures, and up to 24 hours at room temperature. Given this potential disadvantage for BNT162b2, we believe it may be premature to definitively call BNT162b2 the clear-cut winner in the COVID-19 vaccine race.”To this end, Burns reiterates a Neutral (i.e. Hold) rating on BNTX shares without specifying a price target. (To watch Burns’ track record, click here)Overall, the Street is evenly split when assessing BioNTech’s prospects; 4 Buys and Holds, each, coalesce to a Moderate buy consensus rating. However, riding its vaccine candidate’s promise, BNTX shares are up by 207% year-to-date, and the analysts feel the stock has surged enough for now; At $102.43, the projection is for downside of 4% in the coming months. (See BNTX stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
TipRanks · 4h ago
Oil Stocks Are Finally Bouncing Back
A combination of new vaccine breakthroughs, production discipline from OPEC+, and undervalued oil stocks makes the outlook very positive for oil companies
Oilprice.com · 4h ago
Fears of a COVID-inspired crude oil glut? Fading contango tells a different story
Rising COVID-19 cases raise the specter of another global glut of crude oil. But spreads between near- and far-dated oil futures are telling a different story.
MarketWatch · 5h ago
How One Contractor Is Trying To Help Detroit Recover From The Pandemic
The construction business has boomed during the coronavirus pandemic.  That’s according to Seth Helfman, the president at City Contracting Services, one of the biggest contractors in Michigan. Over almost 20 years, Helfman has witnessed countless economic cycles and their impact on construction firsthand.
Benzinga · 6h ago
Doctors say CDC should warn people the side effects from Covid vaccine shots won't be 'a walk in the park'
CNBC.com · 6h ago
A successful Ebola vaccine delivery shows how a Covid-19 vaccine would work in Africa
“We are not starting from scratch in Africa."
Quartz · 8h ago
How Good Is AstraZeneca's Vaccine News?
(Bloomberg Opinion) -- Max Nisen and Sam Fazeli, who cover the pharmaceutical industry for Bloomberg Opinion and Bloomberg Intelligence, answered questions about Covid-19 vaccine trial data released early Monday by AstraZeneca Plc and the University of Oxford. The dialog has been edited and condensed.Astra and Oxford on Monday became the third Covid-19 vaccine developers to announce positive early results from a large trial. But the findings don’t seem as straightforward or uniformly encouraging as those released by Pfizer Inc.-BioNTech SE and Moderna Inc. What should we make of them?Max Nisen: The headline number — an average of 70% protection against Covid-19 disease — is positive but less impressive than the more than 90% efficacy seen from Moderna Inc. and the partnership between Pfizer and BioNTech. The data is also more confusing. The researchers disclosed data on two different dosing regimens: a half dose followed by a full dose resulted in 90% efficacy, while two full doses showed 62%. Sam Fazeli: To my mind, the question really is what is the true efficacy of this vaccine? Why is there a group of subjects in whom the vaccine achieves 90% efficacy and another group that gets 62%? Also, the 90% level came from a group one-quarter the size of the one that hit 62%, so it’s the latter that you should believe in more from a statistical perspective. The company's explanation about dose levels is difficult to understand.Max Nisen: That is a real concern. One possible explanation is this vaccine uses a different technology than Pfizer-BioNTech and Moderna. While theirs use messenger RNA to instruct cells to produce a coronavirus protein that prompts a protective immune response against Covid, Astra’s starts the process by using a harmless virus to insert a gene into cells. The body may react against that virus carrier, making it harder for it to get into cells and generate the right kind of immunity. So it’s possible that a full dose up front actually make the vaccine less effective by giving the body too much familiarity with the carrier virus.Sam Fazeli: Yes, that would potentially explain it, but it creates some additional concerns. For one, a strong reaction to the viral carrier means it will be harder to reuse the vaccine because people will build immunity to the delivery mechanism. Astra could help answer these questions by providing data on how patients in both arms reacted to the carrier virus as well as more information from the seemingly more effective dosing regimen.Max Nisen: Still, even with those caveats, the weaker regimen beats the FDA's 50% threshold for approval. There were also no cases of severe Covid or hospitalizations on the vaccine arm. And it's worth noting other points of differentiation with the mRNA vaccines. AstraZeneca has agreed to sell the vaccine at cost, so each dose is a few dollars. The Pfizer-BioNTech and Moderna vaccines both cost much more, and early supply has been snapped up by richer countries. The Astra vaccine is also much easier to store, which adds to the cost-based appeal for low-income nations. And because of ambitious manufacturing partnerships and the fact that mRNA is a newer technology, there will be many more doses of the Astra shot available. At the end of the day, we'll need to vaccinate the whole world, and broad vaccination with a less effective shot beats having to wait while the others are used very narrowly. Bottom line, there's still a role for this vaccine to fight the pandemic, right?Sam Fazeli: Absolutely. There is nothing wrong with a vaccine that has 70% efficacy, especially in a world that needs as many doses as it can get. And it’s much easier to ship this vaccine around the world than either Moderna’s or Pfizer-BioNTech's vaccines. But the lower efficacy does mean that the many countries that will be relying on this vaccine will need to get a higher percentage of their populations inoculated to achieve the same level of broad protection as nations that will be using the mRNA shots. It is also possible that the Astra vaccine could be used for the time being, but then followed by a booster from other vaccines. One great thing that Astra is doing in its trial and Pfizer-BioNTech and Moderna aren’t is to collect swabs from all participants on a weekly basis, and not just those exhibiting symptoms. This can help address an important question: Does the vaccine stop the virus from spreading, in addition to stopping the development of disease? Once we see this data, the fortunes of Astra's vaccine could suddenly change.Max Nisen: This all raises questions about who gets what vaccine and how the world will make those decisions, especially now that the Astra-Oxford effort has introduced more variety in the data. Many countries have already signed contracts with different vaccine manufacturers and will decide individually how to use the doses they get. There is also some effort toward international cooperation, like the COVAX Facility — an effort by several nonprofits and the World Health Organization to ensure access for developing nations. But in the absence of a single unified process or good comparative data on different vaccines, and given limited early supplies, things could be a bit chaotic. Any thoughts on how this is likely to play out?Sam Fazeli: Indeed, this is what I always worry about. What if we get vaccines with differing upfront efficacy? Or worse, vaccines that have different durability or have varying effects on how well an infection can be controlled? I don't think we have enough data yet to make a decision on this from a longer-term perspective. My concern, though, is that if Astra's efficacy does not improve, it may impact people's interest in being vaccinated with that shot, which will work against the need for the high inoculation rates that are needed to reach herd immunity.Max Nisen: That would be concerning. But at least for now, as I see it, the Astra data suggests its vaccine will be another useful tool in the pandemic fight, even if it comes with questions. We should get more data in the coming days and weeks, and I’m hopeful that it will provide more clarity and confidence. This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.Sam Fazeli is senior pharmaceuticals analyst for Bloomberg Intelligence and director of research for EMEA. For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Bloomberg · 9h ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PFE. Analyze the recent business situations of Pfizer through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 21 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PFE stock price target is 41.78 with a high estimate of 53.00 and a low estimate of 35.00.
EPS
Institutional Holdings
Institutions: 2.69K
Institutional Holdings: 3.83B
% Owned: 68.92%
Shares Outstanding: 5.56B
TypeInstitutionsShares
Increased
1.11K
89.22M
New
250
647.01K
Decreased
916
198.92M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.87%
Pharmaceuticals & Medical Research
-0.36%
Key Executives
Chairman/Chief Executive Officer/Director
Albert Bourla
President
John Young
Chief Financial Officer/Executive Vice President
Frank D'Amelio
Corporate Executive
Angela Hwang
Chief Human Resource Officer/Executive Vice President
Dawn Rogers
Executive Vice President/Chief Technology Officer
Lidia Fonseca
Executive Vice President/Chief Compliance Officer/Chief Risk Officer
Rady Johnson
Executive Vice President/General Counsel
Douglas Lankler
Executive Vice President
Alexander Mackenzie
Executive Vice President
Sally Susman
Senior Vice President/Chief Accounting Officer/Controller
Jennifer Damico
Senior Vice President
Gordon Loh
Chief Scientific Officer
Mikael Dolsten
Lead Director/Independent Director
Shantanu Narayen
Director
Susan Desmond-Hellmann
Independent Director
Ronald Blaylock
Independent Director
Joseph Echevarria
Independent Director
W. Don Cornwell
Independent Director
Wyllie Cornwell
Independent Director
Scott Gottlieb
Independent Director
Helen Hobbs
Independent Director
Susan Hockfield
Independent Director
Dan Littman
Independent Director
Suzanne Nora Johnson
Independent Director
James Quincey
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
09/24/2020
Dividend USD 0.38
11/05/2020
06/25/2020
Dividend USD 0.38
07/30/2020
04/23/2020
Dividend USD 0.38
05/07/2020
12/16/2019
Dividend USD 0.38
01/30/2020
09/24/2019
Dividend USD 0.36
11/07/2019
06/27/2019
Dividend USD 0.36
08/01/2019
04/25/2019
Dividend USD 0.36
05/09/2019
12/14/2018
Dividend USD 0.36
01/31/2019
09/27/2018
Dividend USD 0.34
11/08/2018
06/28/2018
Dividend USD 0.34
08/02/2018
04/26/2018
Dividend USD 0.34
05/10/2018
12/18/2017
Dividend USD 0.34
02/01/2018
09/27/2017
Dividend USD 0.32
11/09/2017
06/23/2017
Dividend USD 0.32
08/02/2017
04/28/2017
Dividend USD 0.32
05/10/2017
12/13/2016
Dividend USD 0.32
02/01/2017
09/23/2016
Dividend USD 0.3
11/08/2016
06/23/2016
Dividend USD 0.3
08/03/2016
04/28/2016
Dividend USD 0.3
05/11/2016
12/16/2015
Dividend USD 0.3
02/03/2016
09/25/2015
Dividend USD 0.28
11/04/2015
06/25/2015
Dividend USD 0.28
08/05/2015
04/23/2015
Dividend USD 0.28
05/06/2015
12/17/2014
Dividend USD 0.28
02/04/2015
10/24/2014
Dividend USD 0.26
11/05/2014
06/26/2014
Dividend USD 0.26
07/30/2014
04/25/2014
Dividend USD 0.26
05/07/2014
12/17/2013
Dividend USD 0.26
02/05/2014
10/25/2013
Dividend USD 0.24
11/06/2013
06/28/2013
Dividend USD 0.24
07/31/2013
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PFE
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Pfizer Inc. stock information, including NYSE:PFE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PFE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PFE stock methods without spending real money on the virtual paper trading platform.